Why Tekla Capital Management Llc Reported Alliqua Biomedical, Inc Position?

February 12, 2018 - By Nellie Frank

 Why Tekla Capital Management Llc Reported Alliqua Biomedical, Inc Position?

Investors sentiment decreased to 0.54 in 2017 Q3. Its down 1.17, from 1.71 in 2017Q2. It is negative, as 6 investors sold Alliqua BioMedical, Inc. shares while 7 reduced holdings. 3 funds opened positions while 4 raised stakes. 9.92 million shares or 8.64% less from 10.86 million shares in 2017Q2 were reported.

Northern Tru Corp owns 30,886 shares or 0% of their US portfolio. Citadel Lc holds 0% of its portfolio in Alliqua BioMedical, Inc. (NASDAQ:ALQA) for 18,721 shares. Ameriprise Fincl stated it has 185,000 shares. Wells Fargo And Mn accumulated 428 shares. Morgan Stanley reported 5,439 shares. Royal Financial Bank Of Canada stated it has 6,000 shares or 0% of all its holdings. J Goldman And Communication L P accumulated 450,000 shares. Lpl Ltd Company holds 35,500 shares or 0% of its portfolio. Deutsche Bank & Trust Ag has invested 0% in Alliqua BioMedical, Inc. (NASDAQ:ALQA). Blackrock Incorporated reported 36,436 shares stake. Two Sigma Lc invested in 56,106 shares. 10,781 were reported by National Bank & Trust Of New York Mellon Corp. National Bank Of America De reported 97 shares. Perceptive Advsr Ltd Liability Corporation accumulated 0.59% or 4.23M shares. Virtu Fincl Lc reported 0% stake.

The New Tekla Capital Management Llc Holding in Alliqua Biomedical, Inc

Tekla Capital Management Llc reported SC 13G/A form with the SEC for Alliqua Biomedical, Inc. Access it here: 000110465918008483. As reported by Tekla Capital Management Llc, the filler owns 3.3% or 165,000 shares of the Health Care–company.

Alliqua Biomedical, Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Tekla Capital Management Llc’s positive view for Alliqua Biomedical, Inc. For a institutional investor managing $1.06 billion in assets and having 8+ experts this is interesting position.

Alliqua Biomedical, Inc Institutional Sentiment

Filings show 40 investors own Alliqua Biomedical, Inc. The ownership in Q3 2015 is low, at Infinity of the outstanding shares. This is increased by 5173965. 16001310 were owned by these investors. 6 funds opened new Alliqua Biomedical, Inc stakes, 20 increased positions. There were 4 that closed positions and 6 reduced them.

Joseph Edelman Perceptive Advisors Llc is an investor bullish on Alliqua Biomedical, Inc, owning 1921951 shares as of Q3 2015 for 0.49% of its portfolio. Pura Vida Investments Llc owns 523000 shares or 0.95% of its portfolio. CA Venbio Select Advisor Llc have 0.70% of its portfolio for 850000 shares. Further, Senzar Asset Management Llc reported stake worth less than 0.01% of its portfolio. The NJ Healthcare Value Capital Llc owns 421000 shares. Alliqua Biomedical, Inc is 1.90% of its portfolio.

Business Profile

Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers SilverSeal.

SEC Form 13G.

Tekla Capital Management Llc website.

Analysts await Alliqua BioMedical, Inc. (NASDAQ:ALQA) to report earnings on March, 6. They expect $-0.70 earnings per share, up 61.11 % or $1.10 from last year’s $-1.8 per share. After $-0.79 actual earnings per share reported by Alliqua BioMedical, Inc. for the previous quarter, Wall Street now forecasts -11.39 % EPS growth.

The stock increased 6.40% or $0.11 during the last trading session, reaching $1.76. About 25,885 shares traded. Alliqua BioMedical, Inc. (NASDAQ:ALQA) has declined 66.38% since February 12, 2017 and is downtrending. It has underperformed by 83.08% the S&P500.

Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company has market cap of $8.75 million. It markets MIST Ultrasound Healing Therapy, a painless, noncontact, low-frequency ultrasound to promote healing; Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix that are human biologic regenerative technologies; and TheraBond 3D Antimicrobial Barrier Systems that promotes an optimal wound healing by creating an antimicrobial barrier that helps protect against infection. It currently has negative earnings. The firm also provides contract manufacturing services, including the development, manufacture, and market of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics.

Alliqua BioMedical, Inc. (NASDAQ:ALQA) Ratings Coverage

Among 3 analysts covering Alliqua Biomedical (NASDAQ:ALQA), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Alliqua Biomedical has $10.0 highest and $1.5000 lowest target. $2.25’s average target is 27.84% above currents $1.76 stock price. Alliqua Biomedical had 12 analyst reports since August 19, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Monday, November 2. As per Friday, November 6, the company rating was maintained by Chardan Capital Markets. On Friday, April 7 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by RBC Capital Markets on Friday, November 6 with “Outperform”. As per Wednesday, January 3, the company rating was maintained by H.C. Wainwright. The firm earned “Neutral” rating on Monday, January 8 by H.C. Wainwright. The firm earned “Buy” rating on Wednesday, February 24 by Chardan Capital Markets. RBC Capital Markets maintained Alliqua BioMedical, Inc. (NASDAQ:ALQA) on Wednesday, February 24 with “Outperform” rating. The firm has “Hold” rating given on Wednesday, August 19 by Zacks. On Wednesday, August 10 the stock rating was maintained by H.C. Wainwright with “Buy”.

More notable recent Alliqua BioMedical, Inc. (NASDAQ:ALQA) news were published by: Globenewswire.com which released: “Alliqua BioMedical, Inc. Reports Second Quarter of Fiscal Year 2017 Financial …” on August 10, 2017, also Globenewswire.com with their article: “Alliqua BioMedical, Inc. Announces Termination of its Agreement to Acquire …” published on February 28, 2017, Globenewswire.com published: “Alliqua BioMedical, Inc. Announces Definitive Asset Purchase Agreement with …” on January 05, 2018. More interesting news about Alliqua BioMedical, Inc. (NASDAQ:ALQA) were released by: Globenewswire.com and their article: “Alliqua BioMedical, Inc. Engages Cowen to Assist in Evaluating Potential …” published on November 09, 2017 as well as Globenewswire.com‘s news article titled: “Alliqua BioMedical, Inc. Announces Partnership with Partners Capital Group to …” with publication date: June 19, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.